• Gunnar H Heine, Sören L Becker, Anja L Scheuer, and Stephan H Schirmer.
• Medizinische Klinik II, AGAPLESION MARKUS KRANKENHAUS, Frankfurt.
• Dtsch. Med. Wochenschr. 2021 Apr 1; 146 (7): 466470466-470.

AbstractOnly fifteen months after the beginning of the COVID-19 pandemic, several vaccines are already available for clinical use. While the spike protein of SARS-CoV-2 constitutes the main target of all predominant SARS-CoV-2 vaccines, they work by different mechanisms (mRNA-based vaccines vs. vector-based vaccines vs. protein-based vaccines).Though there are slight differences regarding the level of protection against mild COVID-19, all five vaccines that have been through phase 3 trials were nearly 100 % effective in preventing severe or fatal cases of COVID-19. The side effects were of short duration.Patients with chronic kidney disease (or other significant comorbidities) were largely excluded from Phase 3 trials, which makes definite recommendations concerning their vaccination difficult. The vaccine's effectiveness may be reduced in that population due to a uremic immune defect and/or immunosuppressive medication. However, these patients have an increased risk for severe or fatal COVID-19, so that they may particularly benefit from the vaccine.Thieme. All rights reserved.

42 keywords...

hide…